Fincar (Finasteride) manufactured by Cipla is prescribed for the management of symptomatic benign prostatic hyperplasia (BPH). It is intended for use in adult males.
The suggested dosage is 5 mg taken once daily, with or without food. Although improvements may be observed early on, it is generally necessary for some patients to undergo treatment with Fincar for at least 6-12 months to evaluate the presence of a beneficial response. Regular follow-up assessments should be conducted to ascertain if there has been a clinical response. There is no need for dosage adjustments in elderly patients with impaired renal function, nor in those with liver impairment. However, caution is advised when administering the drug to patients with liver issues, as finasteride is largely metabolized by the liver.
As not every patient may respond to Fincar, those with a significant residual urine volume and/or severely reduced urinary flow should be closely monitored for signs of obstructive uropathy, as they may not be suitable candidates for this treatment.
Care should be exercised when giving Fincar to patients with liver dysfunction, due to the extensive hepatic metabolism of finasteride. Pregnant women, or those wishing to conceive, should refrain from handling crushed or broken Fincar tablets and avoid contact with the semen of men who are taking Fincar, due to the potential risks to a male fetus.